- Conditions
- HIV/AIDS, Contraception
- Interventions
- tenofovir/emtricitabine, DMPA
- Combination Product · Drug
- Lead sponsor
- Sharon Achilles
- Other
- Eligibility
- 18 Years to 45 Years · Female only
- Enrollment
- 15 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2017 – 2020
- U.S. locations
- 1
- States / cities
- Pittsburgh, Pennsylvania
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 817–840
of 3,448
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Advanced Solid Tumors or Lymphomas
- Interventions
- CA-170
- Drug
- Lead sponsor
- Curis, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 71 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2020
- U.S. locations
- 11
- States / cities
- San Francisco, California • Denver, Colorado • Sarasota, Florida + 7 more
- Conditions
- Solid Tumor
- Interventions
- PYX-106
- Drug
- Lead sponsor
- Pyxis Oncology, Inc
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 47 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 11
- States / cities
- Scottsdale, Arizona • La Jolla, California • Los Angeles, California + 8 more
- Conditions
- Sphingomyelin Lipidosis
- Interventions
- Olipudase alfa
- Drug
- Lead sponsor
- Genzyme, a Sanofi Company
- Industry
- Eligibility
- Up to 17 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2019
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Healthy Volunteers
- Interventions
- Copanlisib (Aliqopa, BAY80-6946), Metformin
- Drug
- Lead sponsor
- Bayer
- Industry
- Eligibility
- 18 Years to 45 Years
- Enrollment
- 13 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018 – 2019
- U.S. locations
- 1
- States / cities
- Austin, Texas
- Conditions
- Solid Tumors
- Interventions
- INCB186748, Cetuximab, GEMNabP, mFOLFIRINOX
- Drug
- Lead sponsor
- Incyte Corporation
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 9
- States / cities
- Santa Monica, California • Denver, Colorado • Washington D.C., District of Columbia + 6 more
- Conditions
- Advanced Solid Tumors
- Interventions
- E6201
- Drug
- Lead sponsor
- Eisai Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 55 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2015
- U.S. locations
- 12
- States / cities
- Scottsdale, Arizona • Los Angeles, California • Las Vegas, Nevada + 9 more
- Conditions
- Multiple Myeloma, Non-Hodgkin Lymphoma, B-Cell Lymphoma
- Interventions
- Tiragolumab, Daratumumab/rHuPH20, Rituximab, Atezolizumab
- Drug
- Lead sponsor
- Genentech, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 41 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2023
- U.S. locations
- 9
- States / cities
- Denver, Colorado • Atlanta, Georgia • Baltimore, Maryland + 6 more
- Conditions
- Venous Thrombosis
- Interventions
- MK-2060, Placebo
- Biological
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 18 Years to 50 Years
- Enrollment
- 23 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2025
- U.S. locations
- 2
- States / cities
- Miami, Florida • Knoxville, Tennessee
- Conditions
- Unspecified Adult Solid Tumor, Protocol Specific
- Interventions
- cetuximab, molecular diagnostic method, immunologic technique, laboratory biomarker analysis
- Biological · Genetic · Other
- Lead sponsor
- University of California, Davis
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 27 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2007
- U.S. locations
- 1
- States / cities
- Sacramento, California
- Conditions
- Healthy
- Interventions
- TG-0054
- Drug
- Lead sponsor
- GPCR Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years to 45 Years
- Enrollment
- 64 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2008 – 2009
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Thromboembolism
- Interventions
- Apixaban
- Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 1 Day to 18 Years
- Enrollment
- 49 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2020
- U.S. locations
- 18
- States / cities
- Little Rock, Arkansas • Orange, California • Hartford, Connecticut + 13 more
- Conditions
- Diabetic Macular Edema
- Interventions
- Teprotumumab
- Drug
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2016
- U.S. locations
- 3
- States / cities
- Beverly Hills, California • St. Petersburg, Florida • Omaha, Nebraska
- Conditions
- Healthy
- Interventions
- ALXN2050, Placebo
- Drug
- Lead sponsor
- Alexion Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021
- U.S. locations
- 1
- States / cities
- Tempe, Arizona
- Conditions
- Opioid Dependence, Buprenorphine Withdrawal Syndrome
- Interventions
- Lofexidine HCl, Lofexidine-matching sugar pill
- Drug
- Lead sponsor
- USWM, LLC (dba US WorldMeds)
- Industry
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013
- U.S. locations
- 1
- States / cities
- Salt Lake City, Utah
- Conditions
- Carcinoma, Non-Small-Cell Lung, Gastric Cancer, Gastroesophageal Junction Cancer
- Interventions
- AZD7789
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 130 Years
- Enrollment
- 136 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2026
- U.S. locations
- 4
- States / cities
- Atlanta, Georgia • Fort Wayne, Indiana • New York, New York + 1 more
- Conditions
- Advanced Solid Tumor
- Interventions
- Lunresertib, RP-3500, Zedoresertib
- Drug
- Lead sponsor
- Debiopharm International SA
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 464 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2028
- U.S. locations
- 17
- States / cities
- Los Angeles, California • San Francisco, California • New Haven, Connecticut + 12 more
- Conditions
- Malignant Solid Tumor
- Interventions
- SAR439459, Cemiplimab REGN2810
- Biological · Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 161 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2022
- U.S. locations
- 6
- States / cities
- Fairway, Kansas • Boston, Massachusetts • Durham, North Carolina + 2 more
- Conditions
- Non-hodgkin Lymphoma
- Interventions
- MT-3724
- Drug
- Lead sponsor
- Molecular Templates, Inc.
- Industry
- Eligibility
- 18 Years to 101 Years
- Enrollment
- 9 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2021
- U.S. locations
- 5
- States / cities
- Whittier, California • Plantation, Florida • Chicago, Illinois + 2 more
- Conditions
- Rheumatoid Arthritis
- Interventions
- JNJ-67484703, Placebo
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 44 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 2
- States / cities
- Anniston, Alabama • Orland Park, Illinois
- Conditions
- Healthy
- Interventions
- AZD1722, Omeprazole
- Drug
- Lead sponsor
- Ardelyx
- Industry
- Eligibility
- 19 Years to 65 Years
- Enrollment
- 18 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2013
- U.S. locations
- 1
- States / cities
- Omaha, Nebraska
- Conditions
- Healthy Volunteers
- Interventions
- E2025, Placebo
- Drug
- Lead sponsor
- Eisai Inc.
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 32 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2024
- U.S. locations
- 1
- States / cities
- San Antonio, Texas
- Conditions
- Healthy Participants, Dyslipidemia
- Interventions
- AZD4954, Placebo
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 171 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 6
- States / cities
- Glendale, California • Inverness, Florida • Jacksonville, Florida + 3 more
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- albiglutide (GSK716155)
- Biological
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 283 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2012
- U.S. locations
- 30
- States / cities
- Dothan, Alabama • Long Beach, California • Riverside, California + 25 more